EMD Millipore and Samsung BioLogics have signed an MOU (Memorandum of Understanding) for a strategic alliance on the biopharmaceutical manufacturing business.

Leah Rosin

August 22, 2014

2 Min Read
EMD Millipore Announces Strategic Alliance on Biopharmaceutical Manufacturing with Samsung BioLogics

Billerica, MA—August 22, 2014EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, announces that EMD Millipore and Samsung BioLogics have signed an MOU (Memorandum of Understanding) for a strategic alliance on the biopharmaceutical business. The alliance is intended to encompass a long-term supply agreement in which EMD Millipore will provide raw materials for biopharmaceutical manufacturing.

Dr. Udit Batra, President and CEO of EMD Millipore, and Benoit Gourdier, head of EMD Millipore’s Process Solutions Asia, were present at the signing ceremony held at Samsung BioLogics’ headquarters in Korea. “Our latest partnership in the biopharmaceutical sector will further strengthen the great relationship Merck KGaA and Samsung have built in other business areas for the past years. It will also help us support Samsung’s initiative in the CMO and biopharmaceutical field,” said Dr. Batra.

EMD Millipore will become an essential raw material supplier for Samsung BioLogics’ 30KL facility as well as its new 150KL facility that is expected to be completed in 2015 at Songdo, Incheon, Korea.

“Samsung BioLogics is delighted to develop a strategic alliance with EMD Millipore, which will not only provide us a stable supply of crucial raw materials but also bring mutual advantages for both companies’ long-term business strategies and competitiveness in the biopharmaceutical industry,” said Dr. TH Kim, President and CEO of Samsung BioLogics.

For more information, please contact [email protected]

About Samsung BioLogics
Samsung BioLogics is a global full-service provider of quality-driven contract process development and cGMP manufacturing to the global biopharmaceutical industry. Our facilities are custom designed for monoclonal & recombinant production with maximum flexibility. Our one-stop services include cell line generation, process and analytical method development, analytical services, clinical and commercial bulk cGMP manufacturing of drug substance and drug product including quality assurance, quality control, regulatory compliance standards & support for our customers. For additional information about the company, please visit http://www.samsungbiologics.com.

About EMD Millipore
EMD Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers’ success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science.

Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 66 countries and 2013 revenues of €2.6 billion. EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.

You May Also Like